The 2024 ESC Guidelines for Chronic Coronary Syndromes: A Paradigm Shift in Risk Stratification and Therapeutic Strategies
DOI:
https://doi.org/10.14738/bjhr.1202.18663Keywords:
Anti-inflammatory therapies, chronic coronary syndromes, coronary computed tomography angiography, dual antiplatelet therapy, ESC guidelinesAbstract
The 2024 European Society of Cardiology (ESC) guidelines on chronic coronary syndromes (CCS) introduce significant refinements in diagnosis, risk stratification, and therapeutic strategies, underscoring a shift toward precision medicine and personalized patient care. Moving beyond traditional phenotype classifications, CCS is now recognized as a spectrum, with risk assessment enhanced by coronary artery calcium scoring (CACS) and the risk factor-weighted clinical likelihood (RF-CL) model, improving predictive accuracy for adverse cardiovascular events. Therapeutic updates include optimized dual antiplatelet therapy (DAPT), clopidogrel monotherapy, and expanded use of P2Y12 inhibitors, aiming to balance ischemic protection with bleeding risks. The guidelines further reinforce the cardiovascular benefits of glucagon-like peptide-1 (GLP-1) receptor agonists and sodium–glucose cotransporter 2 (SGLT2) inhibitors beyond diabetes care. A comparison between ESC 2019 and ESC 2024 underscores a more individualized approach to CCS management, incorporating non-invasive imaging such as coronary computed tomography angiography (CCTA), cardiac magnetic resonance imaging (CMR), and positron emission tomography (PET)/single-photon emission computed tomography (SPECT) to refine diagnostic accuracy, while emphasizing the diamond model for medical therapy tailored to coronary pathophysiology and symptom severity. Additionally, the guidelines explore the role of anti-inflammatory therapies, particularly low-dose colchicine, in reducing cardiovascular events, reinforcing a paradigm shift toward integrated, risk-adapted strategies. These advancements signal a holistic transformation in CCS management, combining precision medicine, cutting-edge imaging tools, and emerging pharmacotherapies to enhance clinical decision-making and long-term patient outcomes, while future research should focus on refining antithrombotic regimens, assessing novel lipid-lowering agents, and evaluating anti-inflammatory strategies to ensure sustained improvements in cardiovascular care.
References
Vrints C, Andreotti F, Koskinas KC, Rossello X, Adamo M, Ainslie J, Banning AP, Budaj A, Buechel RR, Chiariello GA, Chieffo A, Christodorescu RM, Deaton C, Doenst T, Jones HW, Kunadian V, Mehilli J, Milojevic M, Piek JJ, Pugliese F, Rubboli A, Semb AG, Senior R, Ten Berg JM, Van Belle E, Van Craenenbroeck EM, Vidal-Perez R, Winther S; ESC Scientific Document Group. 2024 ESC Guidelines for the management of chronic coronary syndromes. Eur Heart J. 2024; 45:3415-3537. doi: 10.1093/eurheartj/ehae177. Erratum in: Eur Heart J. 2025 Feb 21: ehaf079. doi: 10.1093/eurheartj/ehaf079.
Knuuti J, Wijns W, Saraste A, Capodanno D, Barbato E, Funck-Brentano C, Prescott E, Storey RF, Deaton C, Cuisset T, Agewall S, Dickstein K, Edvardsen T, Escaned J, Gersh BJ, Svitil P, Gilard M, Hasdai D, Hatala R, Mahfoud F, Masip J, Muneretto C, Valgimigli M, Achenbach S, Bax JJ; ESC Scientific Document Group. 2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes. Eur Heart J. 2020; 41:407-477. doi: 10.1093/eurheartj/ehz425. Erratum in: Eur Heart J. 2020; 41:4242. doi: 10.1093/eurheartj/ehz825.
Hamilton-Craig C, Ugander M, Greenwood JP, Kozor R. Stress perfusion cardiovascular magnetic resonance imaging: a guide for the general cardiologist. Heart. 2023; 109:428-433. doi: 10.1136/heartjnl-2022-321630.
Crea F. Thrombotic and bleeding complications during antithrombotic treatment: the need for new therapeutic targets. Eur Heart J. 2023; 44:1767-1770. doi: 10.1093/eurheartj/ehad285.
Wang Z, Zhu S, Zhu J, Jiang Z, Ren Y. Comparison of P2Y12 inhibitors and aspirin in secondary prevention of coronary events: a meta-analysis of RCTs. BMC Cardiovasc Disord. 2025; 25:207. doi: 10.1186/s12872-025-04668-x.
Storey RF. Individualising Antithrombotic Strategies for Acute and Chronic Coronary Syndromes. Interv Cardiol. 2024;19: e07. doi: 10.15420/icr.2023.44.
Ray KK, Bays HE, Catapano AL, Lalwani ND, Bloedon LT, Sterling LR, Robinson PL, Ballantyne CM; CLEAR Harmony Trial. Safety and Efficacy of Bempedoic Acid to Reduce LDL Cholesterol. N Engl J Med. 2019; 380:1022-1032. doi: 10.1056/NEJMoa1803917.
Mansoor T, Rao BH, Gupta K, Parikh SS, Abramov D, Mehta A, Al Rifai M, Virani SS, Nambi V, Minhas AMK, Koshy SKG. Inclisiran as a siRNA Inhibitor of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9); Past, Present, and Future. Am J Cardiovasc Drugs. 2024 Dec 20. doi: 10.1007/s40256-024-00712-x. Epub ahead of print.
Garwood CL, Cabral KP, Brown R, Dixon DL. Current and emerging PCSK9-directed therapies to reduce LDL-C and ASCVD risk: A state-of-the-art review. Pharmacotherapy. 2025; 45:54-65. doi: 10.1002/phar.4635.
Simms-Williams N, Treves N, Yin H, Lu S, Yu O, Pradhan R, Renoux C, Suissa S, Azoulay L. Effect of combination treatment with glucagon-like peptide-1 receptor agonists and sodium-glucose cotransporter-2 inhibitors on incidence of cardiovascular and serious renal events: population-based cohort study. BMJ. 2024;385: e078242. doi: 10.1136/bmj-2023-078242. Erratum in: BMJ. 2024;385: q1094. doi: 10.1136/bmj. q1094. Erratum in: BMJ. 2024 Jun 5;385: q1237. doi: 10.1136/bmj. q1237.
Rosano G, Quek D, Martínez F. Sodium-Glucose Co-transporter 2 Inhibitors in Heart Failure: Recent Data and Implications for Practice. Card Fail Rev. 2020;6: e31. doi: 10.15420/cfr.2020.23. 353
Cersosimo A, Salerno N, Sabatino J, Scatteia A, Bisaccia G, De Rosa S, Dellegrottaglie S, Bucciarelli-Ducci C, Torella D, Leo I. Underlying mechanisms and cardioprotective effects of SGLT2i and GLP-1Ra: insights from cardiovascular magnetic resonance. Cardiovasc Diabetol. 2024; 23:94. doi: 10.1186/s12933-024-02181-7.
Kushner RF, Ryan DH, Deanfield J, Kokkinos A, Cercato C, Wilding J, Burguera B, Wu CC, Craciun AE, Pall D, Hramiak I, Hjelmesæth J, Harder-Lauridsen NM, Weimers P, Jeppesen OK, Kallenbach K, Lincoff AM, Lingvay I. Safety profile of semaglutide versus placebo in the SELECT study: a randomized controlled trial. Obesity (Silver Spring). 2025; 33:452-462. doi: 10.1002/oby.24222.
Sebastian SA, Padda I, Johal G. Cardiovascular-Kidney-Metabolic (CKM) syndrome: A state-of-the-art review. Curr Probl Cardiol. 2024; 49:102344. doi: 10.1016/j.cpcardiol.2023.102344.
Libby P. Inflammation during the life cycle of the atherosclerotic plaque. Cardiovasc Res. 2021 Nov 22;117(13):2525-2536. doi: 10.1093/cvr/cvab303.
Ajala ON, Everett BM. Targeting Inflammation to Reduce Residual Cardiovascular Risk. Curr Atheroscler Rep. 2020; 22:66. doi: 10.1007/s11883-020-00883-3.
Bonaventura A, Potere N, Liberale L, Kraler S, Weber BN, Abbate A. Colchicine in Coronary Artery Disease: Where Do We Stand? J Cardiovasc Pharmacol. 2025; 85:243-247. doi: 10.1097/FJC.0000000000001672.
Svensson EC, Madar A, Campbell CD, He Y, Sultan M, Healey ML, Xu H, D'Aco K, Fernandez A, Wache-Mainier C, Libby P, Ridker PM, Beste MT, Basson CT. TET2-Driven Clonal Hematopoiesis and Response to Canakinumab: An Exploratory Analysis of the CANTOS Randomized Clinical Trial. JAMA Cardiol. 2022; 7:521-528. doi: 10.1001/jamacardio.2022.0386.
Ait-Oufella H, Libby P. Inflammation and Atherosclerosis: Prospects for Clinical Trials. Arterioscler Thromb Vasc Biol. 2024; 44:1899-1905. doi: 10.1161/ATVBAHA.124.320155.
Agnello F, Capodanno D. Anti-inflammatory strategies for atherosclerotic artery disease. Expert Opin Drug Saf. 2022; 21:661-672. doi: 10.1080/14740338.2022.2036717.
Held C, White HD, Stewart RAH, Budaj A, Cannon CP, Hochman JS, Koenig W, Siegbahn A, Steg PG, Soffer J, Weaver WD, Östlund O, Wallentin L; STABILITY Investigators. Inflammatory Biomarkers Interleukin-6 and C-Reactive Protein and Outcomes in Stable Coronary Heart Disease: Experiences from the STABILITY (Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy) Trial. J Am Heart Assoc. 2017;6: e005077. doi: 10.1161/JAHA.116.005077.
Prati F, Albertucci M, Biccire' FG, Gatto L. The role of functional assessment in the management of ischaemic heart disease. Eur Heart J Suppl. 2025;27(Suppl 1): i27-i30. doi: 10.1093/eurheartjsupp/suae121.
Moreno-Angarita A, Peña D, de León JDL, Estacio M, Vila LP, Muñoz MI, Cadavid-Alvear E. Current indications and surgical strategies for myocardial revascularization in patients with left ventricular dysfunction: a scoping review. J Cardiothorac Surg. 2024; 19:469. doi: 10.1186/s13019-024-02844-2.
Yehya A, Lopez J, Sauer AJ, Davis JD, Ibrahim NE, Tung R, Bozkurt B, Fonarow GC, Al-Khatib SM. Revisiting ICD Therapy for Primary Prevention in Patients with Heart Failure and Reduced Ejection Fraction. JACC Heart Fail. 2025; 13:1-13. doi: 10.1016/j.jchf.2024.09.014.
Choi AD, Marques H, Kumar V, Griffin WF, Rahban H, Karlsberg RP, Zeman RK, Katz RJ, Earls JP. CT Evaluation by Artificial Intelligence for Atherosclerosis, Stenosis and Vascular Morphology (CLARIFY): A Multi-center, international study. J Cardiovasc Comput Tomogr. 2021; 15:470-476. doi: 10.1016/j.jcct.2021.05.004.
Lin ZM, Gao HY, Shi SH, Li YT. Mizagliflozin ameliorates diabetes induced kidney injury by inhibitor inhibit inflammation and oxidative stress. World J Diabetes. 2025; 16:92711. doi: 10.4239/wjd. v16.i1.92711. Raja, S. G. (2025). The 2024 ESC Guidelines for Chronic Coronary Syndromes: A Paradigm Shift in Risk Stratification and Therapeutic Strategies.
Bailey CJ, Flatt PR, Conlon JM. Multifunctional incretin peptides in therapies for type 2 diabetes, obesity and associated co-morbidities. Peptides. 2025; 187:171380. doi: 10.1016/j.peptides.2025.171380.
Webb CM, George M, Collins P. The 2024 European Society of Cardiology guidelines for chronic coronary syndromes: good news for angina and non-obstructive coronary artery (ANOCA)/ischaemia and nonobstructive coronary artery (INOCA) patients? Eur Heart J Open. 2025;5: oeaf016. doi: 10.1093/ehjopen/oeaf016.
Sharp RP, Patatanian E, Sirajuddin R. Use of Ranolazine for the Treatment of Coronary Microvascular Dysfunction. Am J Cardiovasc Drugs. 2021; 21:513-521. doi: 10.1007/s40256-020-00462-6.
Cacciapuoti F. Ranolazine and Ivabradine: two different modalities to act against ischemic heart disease. Ther Adv Cardiovasc Dis. 2016; 10:98-102. doi: 10.1177/1753944716636042.
Awasthi S, Sachdeva N, Gupta Y, Anto AG, Asfahan S, Abbou R, Bade S, Sood S, Hegstrom L, Vellanki N, Alger HM, Babu M, Medina-Inojosa JR, McCully RB, Lerman A, Stampehl M, Barve R, Attia ZI, Friedman PA, Soundararajan V, Lopez-Jimenez F. Identification and risk stratification of coronary disease by artificial intelligence-enabled ECG. EClinicalMedicine. 2023; 65:102259. doi: 10.1016/j.eclinm.2023.102259.
Zhang Y, Feng Y, Sun J, Zhang L, Ding Z, Wang L, Zhao K, Pan Z, Li Q, Guo N, Xie X. Fully automated artificial intelligence-based coronary CT angiography image processing: efficiency, diagnostic capability, and risk stratification. Eur Radiol. 2024; 34:4909-4919. doi: 10.1007/s00330-023-10494-6.
Guo B, Jiang M, Guo X, Tang C, Zhong J, Lu M, Liu C, Zhang X, Qiao H, Zhou F, Xu P, Xue Y, Zheng M, Hou Y, Wang Y, Zhang J, Zhang B, Zhang D, Xu L, Hu X, Zhou C, Li J, Yang Z, Mao X, Lu G, Zhang L. Diagnostic and prognostic performance of artificial intelligence-based fully-automated on-site CT-FFR in patients with CAD. Sci Bull (Beijing). 2024; 69:1472-1485. doi: 10.1016/j.scib.2024.03.053.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2025 Shahzad G. Raja
This work is licensed under a Creative Commons Attribution 4.0 International License.
